Alpha 2.0
Login Register
» Articles » PMID: 37165755

Impact of Secondary-type Mutations in NPM1 Mutated AML

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2023 May 11
PMID 37165755
Authors
Qianghua Zhou
Davidson Zhao
Mojgan Zarif
Yu Wing Tony Yeung
Guillaume Richard-Carpentier
Hong Chang
Affiliations
Soon will be listed here.
Citing Articles

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with -mutated AML.

Cocciardi S, Saadati M, Weiss N, Spath D, Kapp-Schwoerer S, Schneider I Hemasphere. 2025; 9(1):e70060.

PMID: 39816531 PMC: 11733593. DOI: 10.1002/hem3.70060.

Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation.

Zhao D, Rumina M, Zarif M, Wei C, Chang H EJHaem. 2024; 5(6):1370-1372.

PMID: 39691238 PMC: 11647738. DOI: 10.1002/jha2.1055.

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.

Zhou Q, Zhao D, Zarif M, Davidson M, Minden M, Tierens A Blood Adv. 2024; 8(7):1760-1771.

PMID: 38286462 PMC: 10985805. DOI: 10.1182/bloodadvances.2023011869.

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

Falini B, Dillon R Blood Cancer Discov. 2023; 5(1):8-20.

PMID: 37917833 PMC: 10772525. DOI: 10.1158/2643-3230.BCD-23-0144.

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.

Eckardt J, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S Leukemia. 2023; 37(11):2282-2285.

PMID: 37679502 PMC: 10624615. DOI: 10.1038/s41375-023-02016-6.